Published in Mol Ther on January 19, 2010
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A (2013) 1.75
Gene therapy for heart failure. Circ Res (2012) 1.46
Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther (2010) 1.34
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Human artificial chromosome (HAC) vector with a conditional centromere for correction of genetic deficiencies in human cells. Proc Natl Acad Sci U S A (2011) 1.21
Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev (2011) 1.18
Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. Nat Nanotechnol (2013) 1.12
A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. Mol Ther (2011) 1.11
Gene therapy on the move. EMBO Mol Med (2013) 1.10
Advances in Gene Delivery Systems. Pharmaceut Med (2011) 1.09
Insertional oncogenesis by non-acute retroviruses: implications for gene therapy. Viruses (2011) 1.09
Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07
A new generation of human artificial chromosomes for functional genomics and gene therapy. Cell Mol Life Sci (2012) 1.06
Overexpression of membrane proteins in mammalian cells for structural studies. Mol Membr Biol (2012) 0.96
Gene therapy for hemophilia. Front Biosci (Landmark Ed) (2015) 0.94
Cellular reprogramming of human peripheral blood cells. Genomics Proteomics Bioinformatics (2013) 0.94
Reprogramming of mesenchymal stem cells derived from iPSCs seeded on biofunctionalized calcium phosphate scaffold for bone engineering. Biomaterials (2013) 0.94
Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. J Clin Invest (2010) 0.93
Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92
A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function. Nucleic Acids Res (2014) 0.91
Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol Biol (2012) 0.91
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int Arch Med (2010) 0.91
Immortalization of human adipose-derived stromal cells: production of cell lines with high growth rate, mesenchymal marker expression and capability to secrete high levels of angiogenic factors. Stem Cell Res Ther (2014) 0.91
A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med (Maywood) (2015) 0.91
Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med (2015) 0.90
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res (2015) 0.89
Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma (2011) 0.87
Gene therapy: light is finally in the tunnel. Protein Cell (2012) 0.87
Functional human artificial chromosomes are generated and stably maintained in human embryonic stem cells. Hum Mol Genet (2011) 0.87
Glucose modulates respiratory complex I activity in response to acute mitochondrial dysfunction. J Biol Chem (2012) 0.86
Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells. Nat Protoc (2015) 0.85
Engineered Viruses as Genome Editing Devices. Mol Ther (2015) 0.84
Creating a flexible multiple microRNA expression vector by linking precursor microRNAs. Biochem Biophys Res Commun (2011) 0.83
Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13. Hum Gene Ther Methods (2012) 0.83
Therapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct. Arch Med Sci (2013) 0.83
Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors. Acta Naturae (2013) 0.83
Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk. Hum Gene Ther (2012) 0.83
Genome resource banking of biomedically important laboratory animals. Theriogenology (2012) 0.83
Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease. Hum Gene Ther (2014) 0.82
Current progress and challenges in HIV gene therapy. Future Virol (2011) 0.82
Proviral HIV-genome-wide and pol-gene specific zinc finger nucleases: usability for targeted HIV gene therapy. Theor Biol Med Model (2011) 0.81
S/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection. Nucleic Acids Res (2014) 0.81
Lentiviral small hairpin RNA knockdown of macrophage inflammatory protein-1γ ameliorates experimentally induced osteoarthritis in mice. Hum Gene Ther (2013) 0.81
Lentiviral transduction of neuronal cells. Methods Mol Biol (2013) 0.80
Lentiviral labeling of mouse and human enteric nervous system stem cells for regenerative medicine studies. Neurogastroenterol Motil (2014) 0.80
Differentiated neuroprogenitor cells incubated with human or canine adenovirus, or lentiviral vectors have distinct transcriptome profiles. PLoS One (2013) 0.79
Migration of bone marrow progenitor cells in the adult brain of rats and rabbits. World J Stem Cells (2016) 0.79
Cell-cell transmission of VSV-G pseudotyped lentivector particles. PLoS One (2013) 0.78
Effect of NELL1 gene overexpression in iPSC-MSCs seeded on calcium phosphate cement. Acta Biomater (2014) 0.78
Kinetics of lentiviral vector transduction in human CD34(+) cells. Exp Hematol (2015) 0.78
Generation of a genome scale lentiviral vector library for EF1α promoter-driven expression of human ORFs and identification of human genes affecting viral titer. PLoS One (2012) 0.78
p27Kip1 knockdown induces proliferation in the organ of Corti in culture after efficient shRNA lentiviral transduction. J Assoc Res Otolaryngol (2013) 0.77
Genetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity. Transplant Proc (2013) 0.77
Simple viral/minimal piggyBac hybrid vectors for stable production of self-inactivating gamma-retroviruses. BMC Res Notes (2015) 0.77
Emerging and future therapies for hemophilia. J Blood Med (2015) 0.77
Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther Methods Clin Dev (2016) 0.77
Zinc finger nucleases for targeted mutagenesis and repair of the sickle-cell disease mutation: An in-silico study. BMC Blood Disord (2012) 0.77
Generation and characterization of the first immortalized alpaca cell line suitable for diagnostic and immunization studies. PLoS One (2014) 0.76
The effect of injection speed and serial injection on propidium iodide entry into cultured HeLa and primary neonatal fibroblast cells using lance array nanoinjection. Springerplus (2016) 0.75
Expression of a biotin acceptor peptide-containing protein with potential incorporation on the lentiviral envelope as a viral surface engineering platform. Res Pharm Sci (2015) 0.75
An Optimized Protocol for Packaging Pseudotyped Integrase Defective Lentivirus. Biol Proced Online (2016) 0.75
Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts. J Vis Exp (2016) 0.75
Evaluation of lentiviral-mediated expression of sodium iodide symporter in anaplastic thyroid cancer and the efficacy of in vivo imaging and therapy. J Oncol (2011) 0.75
Efficient lentiviral transduction of adipose tissue-derived mouse mesenchymal stem cells and assessment of their penetration in female mice cervical tumor model. Iran J Cancer Prev (2014) 0.75
Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells. Front Genet (2013) 0.75
Human fetal liver cells for regulated ex vivo erythropoietin gene therapy. Mol Ther Methods Clin Dev (2014) 0.75
A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development. PLoS One (2014) 0.75
Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma. Plast Reconstr Surg (2015) 0.75
Repeated lentivirus-mediated granulocyte colony-stimulating factor administration to treat canine cyclic neutropenia. Hum Gene Ther (2012) 0.75
CRISPR-Cas9 directed knock-out of a constitutively expressed gene using lance array nanoinjection. Springerplus (2016) 0.75
Differences in vector-genome processing and illegitimate integration of non-integrating lentiviral vectors. Gene Ther (2016) 0.75
A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme. World J Exp Med (2011) 0.75
Engineering cell-based therapies to interface robustly with host physiology. Adv Drug Deliv Rev (2016) 0.75
Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies. Mol Diagn Ther (2016) 0.75
Targeting wild-type Erythrocyte receptors for Plasmodium falciparum and vivax Merozoites by Zinc Finger Nucleases In- silico: Towards a Genetic Vaccine against Malaria. Genet Vaccines Ther (2012) 0.75
Immortalization of pig fibroblast cells by transposon-mediated ectopic expression of porcine telomerase reverse transcriptase. Cytotechnology (2015) 0.75
In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci (2016) 0.75
Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes Dis (2017) 0.75
An optimized gene transfection system in WERI-Rb1 cells. Int J Mol Med (2017) 0.75
Leucine-rich repeat-containing G protein-coupled receptor 4 facilitates vesicular stomatitis virus infection by binding vesicular stomatitis virus glycoprotein. J Biol Chem (2017) 0.75
Genetic Modification of T Cells. Biomedicines (2016) 0.75
AAV-based dual-reporter circuit for monitoring cell signaling in living human cells. J Biol Eng (2017) 0.75
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2007) 21.93
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
Generation of mouse induced pluripotent stem cells without viral vectors. Science (2008) 15.25
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A (2008) 13.09
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science (2007) 12.41
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature (2009) 11.27
Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol (2008) 10.97
Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell (2008) 10.68
Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol (2008) 10.63
Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol (2008) 10.29
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 9.23
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 8.80
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol (2008) 6.82
Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 6.50
Gene targeting using zinc finger nucleases. Nat Biotechnol (2005) 6.24
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09
Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature (2006) 5.83
Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells (2009) 5.69
Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med (2004) 5.59
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol (2007) 5.36
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A (2005) 5.29
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 5.24
Gene therapy: therapeutic gene causing lymphoma. Nature (2006) 4.89
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet (1997) 4.26
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods (2008) 3.55
Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol (2004) 3.48
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A (1997) 3.40
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med (2006) 3.22
Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science (2003) 3.21
Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 3.10
Self-complementary AAV vectors; advances and applications. Mol Ther (2008) 3.10
Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem (2004) 3.10
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature (2000) 2.84
Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods (2004) 2.84
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81
Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med (2005) 2.80
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci (2005) 2.75
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 2.70
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell (2008) 2.46
Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet (2001) 2.36
Targeted cell entry of lentiviral vectors. Mol Ther (2008) 2.34
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood (2007) 2.28
Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells (2009) 2.01
Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther (2008) 2.00
Gene delivery by lentivirus vectors. Mol Biotechnol (2007) 1.98
Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther (2005) 1.93
In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther (2001) 1.93
Transient gene expression by nonintegrating lentiviral vectors. Mol Ther (2006) 1.89
Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med (2001) 1.85
Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther (2007) 1.81
Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A (1999) 1.80
Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol (2001) 1.80
Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther (2008) 1.78
Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A (2006) 1.74
Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood (2009) 1.73
Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest (2004) 1.73
Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A (2006) 1.71
In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood (2007) 1.69
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest (2006) 1.69
Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med (2006) 1.67
Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet (2000) 1.62
Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest (2004) 1.59
Continuous high-titer HIV-1 vector production. Nat Biotechnol (2003) 1.58
An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood (2007) 1.57
Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest (2006) 1.54
Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia. Blood (2004) 1.54
Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood (2009) 1.49
Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther (2009) 1.47
Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther (2009) 1.46
Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia (2007) 1.43
Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost (2007) 1.41
Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther (2002) 1.41
Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther (2002) 1.39
Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther (2001) 1.37
Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther (2000) 1.36
Production and titration of lentiviral vectors. Curr Protoc Hum Genet (2007) 1.36
Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia (2008) 1.35
'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther (2003) 1.35
Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol (2007) 1.33
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol (2003) 2.34
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Atonal homolog 1 is a tumor suppressor gene. PLoS Biol (2009) 1.76
Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood (2010) 1.68
Comparative analysis of transposable element vector systems in human cells. Mol Ther (2010) 1.66
Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood (2009) 1.49
IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol (2009) 1.35
Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. J Pathol (2011) 1.19
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells (2005) 1.18
Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther (2013) 1.16
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood (2002) 1.11
Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods (2009) 1.09
Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases. Nucleic Acids Res (2012) 1.09
Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost (2004) 1.07
In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness. J Immunol (2009) 1.05
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol (2008) 1.02
PiggyBac toolbox. Methods Mol Biol (2012) 1.01
Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation (2009) 1.00
Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver. Hepatology (2014) 1.00
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood (2006) 0.99
Bone marrow stromal cells as targets for gene therapy. Curr Gene Ther (2002) 0.98
Oncoretroviral and lentiviral vector-mediated gene therapy. Methods Enzymol (2002) 0.95
Recent progress in gene therapy for hemophilia. Hum Gene Ther (2012) 0.92
Growth, differentiation, transplantation and survival of human skeletal myofibers on biodegradable scaffolds. Biomaterials (2008) 0.89
Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. Hum Gene Ther (2003) 0.89
Preclinical and clinical progress in hemophilia gene therapy. Curr Opin Hematol (2010) 0.87
Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. Stem Cells (2010) 0.85
Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med (2010) 0.85
Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc Res (2012) 0.84
Moving gene therapy forward with mobile DNA. Hum Gene Ther (2009) 0.84
Transposon-mediated gene transfer into adult and induced pluripotent stem cells. Curr Gene Ther (2011) 0.83
Biosafety of adenoviral vectors. Curr Gene Ther (2003) 0.83
Preclinical gene therapy studies for hemophilia using adenoviral vectors. Semin Thromb Hemost (2004) 0.82
Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. J Gene Med (2002) 0.82
Biosafety of onco-retroviral vectors. Curr Gene Ther (2003) 0.79
Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies. Semin Thromb Hemost (2004) 0.79
Optimizing delivery and expression of designer nucleases for genome engineering. Hum Gene Ther Methods (2013) 0.78
Gene therapy delivers. Hum Gene Ther (2009) 0.77
Xenogeneic liver models for gene therapy. Hum Gene Ther (2010) 0.75
Corrigendum: Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells. Nat Protoc (2015) 0.75